A Prospective, Non-Randomized Clinical Study on the Efficacy of Oocyte Retrieval Following G-CSF Priming in Cases with Severe Ovarian Reserve Insufficiency

Prospective Evaluation of Oocyte Yield After Granulocyte Colony-Stimulating Factor Priming in Women with Severe Diminished Ovarian Reserve: A Non-Randomized Clinical Investigation - PEORY-G (Prospective Evaluation of Oocyte Retrieval Yield with G-CSF)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052346

Enrollment

220

Registered

2023-09-28

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Initiate the oocyte retrieval cycle following subcutaneous administration of 300ug of G-CSF (Filgrastim BS Injection 300ug Syringe F) during the early luteal phase. Initiate the oocyte retrieval cycle

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Participants must be aged 20 years or older. Participants must have a history of at least one cancelled oocyte retrieval cycle due to lack of follicular development. Participants must be diagnosed with Diminished Ovarian Reserve (DOR) by a qualified physician. Participants must have no prior history of pregnancy. Participants must not have any other underlying medical conditions. Participants must provide written informed consent, acknowledging an understanding of the study's objectives and procedures.

Exclusion criteria

Exclusion criteria: Participants experiencing mental instability or other factors that would make participation in the study difficult are excluded.

Design outcomes

Primary

Measure	Time frame
Oocyte retrieval success rate in the subsequent cycle following G-CSF priming.	—

Secondary

Measure	Time frame
Cumulative oocyte retrieval success rate up to six months post-G-CSF treatment. Cumulative pregnancy rate up to six months post-G-CSF treatment. Follicular growth metrics observed after G-CSF priming. Changes in Anti-Mullerian Hormone (AMH) levels post-G-CSF treatment. Time duration from G-CSF injection to successful oocyte retrieval within six months post-treatment. Time duration from G-CSF injection to clinical pregnancy confirmation within six months post-treatment. Incidence of adverse events observed post-G-CSF administration.	—

Measure

Time frame

Cumulative oocyte retrieval success rate up to six months post-G-CSF treatment. Cumulative pregnancy rate up to six months post-G-CSF treatment. Follicular growth metrics observed after G-CSF priming. Changes in Anti-Mullerian Hormone (AMH) levels post-G-CSF treatment. Time duration from G-CSF injection to successful oocyte retrieval within six months post-treatment. Time duration from G-CSF injection to clinical pregnancy confirmation within six months post-treatment. Incidence of adverse events observed post-G-CSF administration.

—

Countries

Japan

Contacts

Public ContactShinnosuke Komiya

HORAC Grand Front Osaka Clinic Gynecology

komiya0703@gmail.com0636778824

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026